Ipilimumab for advanced melanoma: A pharmacologic perspective

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 3, 2013, Pages 195-201

  Trinh, Van Anh ^a   Hagen, Brenda ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

advanced melanoma; cytotoxic T lymphocyte antigen 4; Ipilimumab; pharmacology

Indexed keywords

BUDESONIDE; CORTICOSTEROID; GLYCOPROTEIN GP 100; IPILIMUMAB; PEPTIDE VACCINE; PLACEBO; PREDNISONE;

ABDOMINAL PAIN; ADVANCED CANCER; ADVERSE OUTCOME; ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG CLEARANCE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPISCLERITIS; ETHNICITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEPATITIS; HUMAN; HYPOTENSION; ILEUS; INTESTINE PERFORATION; IRITIS; LIVER FUNCTION TEST; MELANOMA; MUSCLE WEAKNESS; NEUROPATHY; PARESTHESIA; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; TREATMENT RESPONSE; UVEITIS; VALIDATION PROCESS;

ADVANCED MELANOMA; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PHARMACOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MELANOMA;

EID: 84882277242     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212459100     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 ; 62: 10-29
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006 ; 355: 51-65
3. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 ; 26: 527-534
4. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009 ; 9: 587-595
5. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 ; 17: 2105-2116
6. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009 ; 229: 12-26
7. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012 ; 65: 9-22
8. Bristol-Myers Squibb. Ipilimumab US prescribing information 2011, http://packageinserts.bms.com/pi/pi-yervoy.pdf (2011, accessed 11 December 2011).
9. YERVOY™ (ipilimumab) Summary of product characteristics. Uxbridge, UK. http://www.medicines.org.uk/emc/medicine/24779 (2011, accessed 9 March 2012).
10. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated, advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010 ; 11: 155-164
11. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003 ; 100: 8372-8377
12. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol. 2005 ; 12: 1005-1016
13. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011 ; 29: 489-498
14. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 ; 363: 711-723
15. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 ; 364: 2517-2526
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009 ; 15: 7412-7420
17. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010 ; 37: 533-546
18. Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. Presented at the American Society of Clinical Oncology 2011 Annual Meeting, Chicago, IL, USA, 3 - 7 June 2011, Poster 8583.
19. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011 ; 9: 277-286
20. Bristol-Myers Squibb. Ipilimumab US prescribing information: risk evaluation and mitigation strategy. http://www.yervoy.com/hcp/rems.aspx. (2011, accessed 11 December 2011).
21. Amin A, de Pril V, Hamid O, et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol. 2009 ; 27 :
22. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009 ; 15: 5591-5598
23. National Comprehensive Cancer Network. Melanoma. Version 3.2012. National Comprehensive Cancer Network website. http://www.nccn.org/professionals/ physician-gls/pdf/melanoma.pdf (2012, accessed 11 March 2012).